Edition:
United States

TG Therapeutics Inc (TGTX.OQ)

TGTX.OQ on NASDAQ Stock Exchange Capital Market

7.83USD
18 Apr 2019
Change (% chg)

$-0.31 (-3.81%)
Prev Close
$8.14
Open
$8.20
Day's High
$8.20
Day's Low
$7.50
Volume
450,588
Avg. Vol
557,443
52-wk High
$15.95
52-wk Low
$3.41

Latest Key Developments (Source: Significant Developments)

TG Therapeutics Announces About $85 Mln In Equity And Debt Financings
Friday, 1 Mar 2019 09:00am EST 

March 1 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS ANNOUNCES APPROXIMATELY $85 MILLION IN EQUITY AND DEBT FINANCINGS.TG THERAPEUTICS INC - COMPANY PRICED A PUBLIC OFFERING OF ITS COMMON STOCK FOR GROSS PROCEEDS OF APPROXIMATELY $25.2 MILLION.TG THERAPEUTICS INC - COMPANY ANTICIPATES USING NET PROCEEDS FROM OFFERING TO FUND ONGOING DEVELOPMENT OF UBLITUXIMAB AND UMBRALISIB.  Full Article

TG Therapeutics Qtrly Loss Per Share $0.43
Friday, 9 Nov 2018 07:30am EST 

Nov 9 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS, INC. PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.TG THERAPEUTICS INC QTRLY LOSS PER SHARE $0.43.TG THERAPEUTICS - BELIEVES CASH, CASH EQUIVALENTS ON HAND AS OF SEPT 30, WILL BE SUFFICIENT TO FUND CO'S PLANNED OPERATIONS THROUGH END OF 2019.  Full Article

TG Therapeutics Inc QTRLY Loss Per Share $0.59
Tuesday, 7 Aug 2018 04:00pm EDT 

Aug 7 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS, INC. PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.TG THERAPEUTICS INC QTRLY LOSS PER SHARE $0.59.TG THERAPEUTICS - CASH, CASH EQUIVALENTS, INVESTMENT SECURITIES, AND INTEREST RECEIVABLE WERE $126.3 MILLION AS OF JUNE 30, 2018.TG THERAPEUTICS - CASH, CASH EQUIVALENTS, INVESTMENT SECURITIES, INTEREST RECEIVABLE ON HAND AT QUARTER END ENOUGH TO FUND PLANNED OPERATIONS INTO H2 2019.  Full Article

TG Therapeutics Reports Qtrly Loss Per Share Of $0.59
Tuesday, 8 May 2018 07:30am EDT 

May 8 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS, INC. PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.CASH, CASH EQUIVALENTS, INVESTMENT SECURITIES, AND INTEREST RECEIVABLE WERE $109.2 MILLION AS OF MARCH 31, 2018.QTRLY LOSS PER SHARE $0.59.Q1 EARNINGS PER SHARE VIEW $-0.44 -- THOMSON REUTERS I/B/E/S.TG THERAPEUTICS-CASH, CASH EQUIVALENTS, INVESTMENT SECURITIES, INTEREST RECEIVABLE ON HAND AS OF MARCH 31, SUFFICIENT TO FUND OPERATIONS THROUGH MID-2019.  Full Article

TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies
Monday, 8 Jan 2018 07:30am EST 

Jan 8 (Reuters) - Jiangsu Hengrui Medicine Co Ltd <600276.SS>::TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES.TG THERAPEUTICS INC - ‍ UNDER TERMS, HENGRUI WILL RECEIVE AN UP-FRONT LICENSING FEE AND NEAR-TERM MILESTONES, PAYABLE IN TG COMMON STOCK​.TG THERAPEUTICS INC - ‍HENGRUI IS ELIGIBLE TO RECEIVE COLLABORATION AND LICENSING PAYMENTS OF ABOUT $350 MILLION, IN ADDITION TO ROYALTIES ON FUTURE SALES​.  Full Article

TG Therapeutics Announces Initiation Of Randomized Phase II Trial In Follicular Lymphoma
Monday, 27 Nov 2017 07:30am EST 

Nov 27 (Reuters) - TG Therapeutics Inc ::TG THERAPEUTICS ANNOUNCES INITIATION OF NATIONAL CANCER INSTITUTE/SWOG-SPONSORED RANDOMIZED PHASE II TRIAL IN FOLLICULAR LYMPHOMA.  Full Article

TG Therapeutics qtrly net loss per common share $0.48
Wednesday, 8 Nov 2017 07:30am EST 

Nov 8 (Reuters) - TG Therapeutics Inc ::TG therapeutics, inc. Provides business update and reports third quarter 2017 financial results.TG therapeutics inc - qtrly net loss per common share $0.48.Q3 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S.TG therapeutics inc - believes cash and cash equivalents will be sufficient to fund planned operations through 2018​.  Full Article

TG Therapeutics announces completion of full enrollment in UNITY-CLL phase 3 trial
Monday, 16 Oct 2017 07:30am EDT 

Oct 16 (Reuters) - TG Therapeutics Inc : :TG Therapeutics announces completion of full enrollment in the UNITY-CLL phase 3 trial.TG Therapeutics Inc - ‍targeting an NDA/BLA filing for combination of TGR-1202 + TG-1101 in 2H18​.TG Therapeutics Inc - ‍top-line ORR data from UNITY-CLL trial expected in 2Q18​.  Full Article

TG Therapeutics ‍says FDA confirms accelerated approval for TG-1101 based on overall response rate a review issue
Monday, 16 Oct 2017 07:30am EDT 

Oct 16 (Reuters) - TG Therapeutics Inc : :TG Therapeutics provides update on fda meeting for genuine phase 3 trial.TG Therapeutics - co ‍has met with U.S. FDA regarding use of results from genuine phase 3 trial to support bla filing for approval of TG-1101​.TG Therapeutics Inc - ‍fda confirmed that accelerated approval for TG-1101 based on overall response rate would be a review issue ​.TG Therapeutics - ‍FDA asked co to consider future available therapy in risk/benefit analysis in future BLA filing that may impact accelerated approval.TG Therapeutics - co, FDA also discussed potential use of progression free survival results from genuine trial to support full approval of TG-1101​.TG Therapeutics Inc - ‍plans to have a follow-up meeting with FDA to discuss use of PFs endpoint in more detail before end of year​.  Full Article

TG Therapeutics says phase 3 ULTIMATE trials evaluating TG-1101 in multiple sclerosis patients are now open for enrollment
Friday, 15 Sep 2017 07:30am EDT 

Sept 15 (Reuters) - TG Therapeutics Inc :TG Therapeutics Inc announces the phase 3 ultimate trials evaluating tg-1101 in patients with multiple sclerosis are now open for enrollment.TG Therapeutics Inc - ‍ ULTIMATE I and ULTIMATE II phase 3 trials will each enroll approximately 440 subjects, randomized in a 1:1 ratio.  Full Article